Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT05639673 Recruiting - Heart Failure Clinical Trials

Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia

Start date: December 15, 2022
Phase:
Study type: Observational

Survival rates for childhood acute lymphoblastic leukemia (ALL) exceeds 90%, making a growing population of survivors susceptible to treatment-related late-effects of which some are both severe and disabling. However, late effects are not captured systematically, hence hampering the quantification of long-term toxicity. An international collaboration of ALL consortia recently defined 21 severe health conditions designated Severe Toxicities representing the objectively most severe toxicities following ALL treatment, which should be captured and included in the evaluation of the burden of therapy in the form of Severe Toxicity Free Survival (STFS). With this study we aim to evaluate the prevalence of 21 Severe Toxicities and the according Severe Toxicity Free Survival in 5 cohorts each consisting of > 1000 pediatric ALL patients across Europe, USA, and Australia. This will be the first step in the global implementation of a consensus-based reporting of late effects following ALL treatment allowing future treatment outcome evaluation to include severe toxicities.

NCT ID: NCT05639452 Recruiting - Clinical trials for Deterioration of Patients' General Condition

Development of an Early Warning Score for Detecting the Deterioration of a Patients' General Condition in an Acute Hospital

Start date: October 5, 2022
Phase:
Study type: Observational

An acute deterioration of a patients' general condition is often preceded by changes in individual vital parameters. An early warning system (EWS) shall be developed with a reduced number of physiological and individual parameters, compared to conventional early warning systems; and an algorithm will be generated that is able to predict clinical deterioration. Its predictive power and accuracy shall be investigated. In a second exploratory phase, different model variants will be analyzed and the applicability of the model variants in the context of continuous EWS on wearables will be examined.

NCT ID: NCT05638620 Recruiting - SARS-CoV2 Infection Clinical Trials

Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID

DSBLongCOVID
Start date: December 1, 2022
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms.

NCT ID: NCT05638490 Recruiting - Clinical trials for Prenatal Diagnosis and Closed-loop Management System of Congenital Talipes Equinovarus

Study on Prenatal Diagnosis and Closed-loop Management System of Congenital Talipes Equinovarus

Start date: August 3, 2022
Phase:
Study type: Observational

The study intends to establish a closed-loop management from prenatal to postnatal through prospective cohort, and comprehensively utilize ultrasound and MRI technology to establish a prenatal diagnosis and evaluation system for congenital talipes equinovarus. On the basis of existing genetic testing, further use of whole-exome sequencing and other genomic methods to explore possible pathogenic genes and loci, and clarify the pathogenic mechanism of congenital talipes equinovarus. Therefore, congenital talipes equinovarus can improve its diagnosis and treatment capacity, reduce the disability rate related to congenital talipes equinovarus, and prevent it well.

NCT ID: NCT05637879 Not yet recruiting - Clinical trials for Post Traumatic Stress Disorder

RCT of Glecaprevir/Pibrentasvir for the Treatment of PTSD

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

The goal of this randomized control trial is to measure the effect of an antiviral medication, Glecaprevir/Pibrentasvir (GLE/PIB), on symptoms of post-traumatic stress disorder. The main questions this study will answer are: Is GLE/PIB effective in improving PTSD symptoms? What is the tolerability of GLE/PIB in those experiencing PTSD? Participants will be randomized into one of two study arms, active medication, or inactive medication (placebo), take active or placebo medication once a day for 8-weeks, provide blood samples at two time points, and complete surveys at eight time points during the eight-month study period.

NCT ID: NCT05637320 Not yet recruiting - Anxiety Disorders Clinical Trials

Big Feelings: A Study on Children's Emotions in Therapy

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about how psychotherapy works for children and adolescents aged 8 - 15 with anxiety, depression, trauma, or disruptive behaviour. The main question it aims to answer is: • Is the biobehavioural regulation of negative emotion a transdiagnostic mechanism of treatment response in psychotherapy for children with anxiety, depression, trauma and/or disruptive behaviour? Children and their parents will be randomly assigned to an evidence-based, transdiagnostic treatment (the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems; MATCH-ADTC) or a waitlist control condition. Participants in both groups will complete a baseline assessment, weekly measures consisting of brief symptom scales and medication tracking, and quarterly assessments every 3 months. Following the intervention/waitlist period, our team will conduct post-test assessments. All assessments, except for the weekly surveys, will consist of symptom scales, clinical interviews, experimental tasks and physiological measures.

NCT ID: NCT05636202 Not yet recruiting - Clinical trials for To Clarify and Verify the Value of NLR in the Diagnosis and Poor Prognosis of Sepsis.c

The Role of Neutrophil-lymphocyte Ratio in the Diagnosis and Prognosis Evaluation of Sepsis: a Single-center, Retrospective Study

Start date: December 1, 2022
Phase:
Study type: Observational

Neutrophil-lymphocyte ratio (NLR), as an inflammatory index, is cheap and easy to obtain, and could be widely used in hospitals at all levels. NLR is a valuable biomarker that is significantly correlated with the status of immune and inflammatory responses. In the past few years, NLR has been continuously and extensively explored in various diseases, and the research progress is considerable. In cardiovascular disease, NLR can predict arrhythmia and short - and long-term mortality in patients with acute coronary syndrome. NLR may be associated with heart failure and valvular heart disease. Moreover, NLR has been shown to be associated with respiratory diseases (such as chronic obstructive pulmonary disease), immune diseases (rheumatoid arthritis and systemic lupus erythematosus), and digestive diseases (acute appendicitis, hepatocellular carcinoma, liver fibrosis, and cirrhosis). Importantly, the study of NLR in sepsis has received much attention in recent years. A 2019 meta-analysis concluded that peripheral white blood cell ratios, including NLR, lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR), are associated with clinical outcomes in sepsis and are useful biomarkers of infection. They recommended that NLR be evaluated in future hierarchical models, To clarify its relationship with NLR and clinical outcome and the prognostic value of NLR, it is worth mentioning that NLR has also been found to have the ability to predict the outcome of sepsis. In 2019, Martins et al. and Westerdijk et al. came to a similar conclusion by analyzing two retrospective studies that NLR, together with other inflammatory parameters, might be a marker for early detection of sepsis in the intensive care unit. However, a large body of evidence demonstrating the association between NLR and adverse clinical outcomes in sepsis remains controversial. Another study concluded that "no association was found between NLR and 28-day in-hospital mortality in patients with sepsis". In addition, the reliability of NLR on admission in predicting the prognosis of critical illness was also lower than that of traditional markers (including CRP, PCT, serum lactic acid and APACHEⅡ score).

NCT ID: NCT05636033 Not yet recruiting - Clinical trials for Alcohol Use Disorder

Semantic Networks in Alcohol Use Disorder Patients: Exploratory Study

ALCOOLNET
Start date: December 2022
Phase:
Study type: Observational

Alcohol Use Disorder (AUD) is a major public health problem, characterized by a high rate of relapse. Chronic and excessive alcohol consumption notably induces frontal brain alterations and cognitive impairments such as executive dysfunction and an attentional bias for alcohol, participating to the risk of relapse. In effect, AUD patients preferentially process alcohol-related cues, which could reflect a reorganization of the patients' semantic network. The investigators hypothesize that in AUD patients, semantic associations in memory are reorganized with a higher centrality of alcohol-related elements. To the investigators knowledge, no studies have explored semantic associations and/or semantic networks in AUD. A study, conducted in patients with neurological damage, showed that frontal lesions are associated with excessive strength in semantic associations, and difficulties to generate remote associations. This excessive strength in semantic associations could reduce the ability to inhibit automatisms and to adapt to new context. Objective: The objective of this study is to explore whether and how AUD patients have a different organization of semantic associations than healthy controls, and whether this reorganization influences the alcohol consumption over the months following the withdrawal. The investigators will also explore how it relates to neuropsychological assessment of flexibility, executive functions, and impulsivity. To these purposes, the investigators will use two original verbal tasks (Free Generation of Associates Task, FGAT and Associative Judgment Task, AJT) assessing word associations and allowing the estimation of semantic networks using graph theory, in combination with neuropsychological testing, in AUD patients and in healthy controls. Methods: This study will include a group of 30 AUD patients and a group of 30 healthy controls. Both groups will be assessed twice, at baseline (T1; early in abstinence for AUD patients) and after a three-month period (T3). For the two groups, T1 and T3 assessments will include the two semantic association tasks (FGAT and AJT). For AUD patients, assessments will also involve neuropsychological testing of impulsivity, flexibility, and attentional bias. Besides, in AUD patients, data about alcohol consumptions will be collected six weeks (T2) and three months (T3) following the baseline assessment to classify patients as relapsers or abstainers.

NCT ID: NCT05635760 Recruiting - Clinical trials for Autism Spectrum Disorder

Parent-implemented Social Communication Treatment in Preschool Children With Autism Spectrum Disorder

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

An accumulation of research evidence has pointed to parent-implemented communication treatment as effective in reducing the severity of social communication deficits in preschool children with ASD. Despite even high-quality evidence, real-world translation to clinical practice remains challenging, especially for children from lower-income families, for two reasons. First, the treatment outcome is highly variable despite study-level efficacy data, most likely due to unique child and parent factors that make treatment response uneven across individual children. Second, the cost of intervention with the largest effect sizes remains high due to its one-on-one format. With the overarching goal to reduce cost and to increase treatment effectiveness at the individual-child level, this project will conduct a randomized controlled trial (RCT) to compare the effectiveness of two options for intervention to address two specific objectives. The investigators will first ascertain whether parent-implemented communication treatment taught by a speech therapist in a Group format (up to 8 families learning together) is more effective than treatment learnt by the parents themselves in a Passive Control format (learning the same materials without the guidance of a therapist) at the study level. The investigators will then evaluate what combinations of parent and child behavioral factors determine which format of intervention is likely to be more effective at the individual-child level. It is likely that not all families require the more costly Group format of intervention. Machine learning analytics with cross-validation will be used in constructing predictive models of treatment response, which will increase the likelihood of these models being generalizable to new patients. This study will be among the first examples of fulfilling the promise of Precision Medicine in providing guidance to patients and families with developmental disorders not about whether to receive intervention but which option for intervention to receive in the context of multiple options. This predict-to prescribe approach of ASD intervention will likely lead to a paradigm shift in clinical practice and ultimately result in lowering the overall cost and increasing the effectiveness of intervention for children with ASD as individuals.

NCT ID: NCT05634486 Recruiting - Clinical trials for Functional Neurological Disorder

Efficacy of the Multidisciplinary Treatment to the Quality of Life of With Functional Movement Disorders

Start date: June 15, 2022
Phase: N/A
Study type: Interventional

Randomized-clinical trial of multidisciplinary approach versus psychoeducation in patients with functional movement disorders: impact to their quality of life and their caregivers' quality of life. Patients with functional movement disorders are randomized in two arms of a one-month treatment (physiotherapy + cognitive-behavioral therapy versus psychoeducational as sham intervention) with a 3-month and 5-month follow-up where the investigators will measure the change in the patients' and caregivers' quality of life. Movement disorders specialists will review the severity of symptoms as blinded raters in the 3th-month and 5th-month follow-up.